Aytu Biopharma IncNASDAQ:AYTU
- LAST PRICE2.8000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.6000/ 9
- Ask / Lots2.9300/ 3
- Open / Previous Close0.0000 / 2.8000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AYTU |
|---|---|---|
| 09:38 ET | 500 | 2.8 |
| 10:26 ET | 7341 | 2.6601 |
| 11:04 ET | 250 | 2.7 |
| 11:45 ET | 1316 | 2.68 |
| 11:49 ET | 100 | 2.67 |
| 12:02 ET | 387 | 2.65 |
| 12:38 ET | 492 | 2.6398 |
| 12:54 ET | 100 | 2.63 |
| 01:44 ET | 1000 | 2.6396 |
| 02:24 ET | 831 | 2.65 |
| 03:05 ET | 200 | 2.6401 |
| 03:45 ET | 160 | 2.6769 |
| 03:59 ET | 154 | 2.8 |
Apr 3, 2024
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024, from 9:03AM ET on Wednesday Apr 03, 2024 by Dow Jones
9:03AM ET on Wednesday Apr 03, 2024 by Dow JonesPresenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now, from 7:01AM ET on Wednesday Apr 03, 2024 by Dow Jones
7:01AM ET on Wednesday Apr 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aytu Biopharma Inc | 15.6M | -0.7x | --- |
Kali Inc | 1.0K | 0.0x | --- |
Journey Medical Corp | 47.4M | -9.7x | --- |
Interpharm Holdings Inc | 70.0 | 0.0x | --- |
Lifecore Biomedical Inc | 193.4M | -3.0x | --- |
Rockwell Medical Inc | 43.8M | -2.7x | --- |
Company Information
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
Contact Information
- Headquarters
- 7900 E. Union Avenue, Suite 920DENVER, CO, United States 80237
- Phone
- 720-437-6580
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer
- Joshua Disbrow
- Chief Financial Officer, Treasurer, Company Secretary
- Mark Oki
- Chief Commercial Officer
- Greg Pyszczymuka
- Independent Director
- Carl Dockery
- Independent Director
- John Donofrio
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.6M |
|---|---|
Revenue (TTM) | $98.5M |
Shares Outstanding | 5.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.24 |
EPS | $-4.06 |
Book Value | $7.13 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 0.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -7.64% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
